196170

Alteogen is a biotechnology company that researches, develops, and commercializes biopharmaceuticals, including biosimilars and biobetters. The company operates a platform technology business, licensing its proprietary Hybrozyme technology to convert intravenous infusions into subcutaneous injections, as well as NexP Fusion and NexMab ADC technologies. Key products include ALT-B4 (berahyaluronidase alfa), the standalone hyaluronidase product Tergase (ALT-BB4), and the Eylea biosimilar Eyluxvi (ALT-L9). Alteogen has established license-out agreements with global pharmaceutical partners such as MSD, AstraZeneca, GSK, Daiichi Sankyo, Sandoz, and Novartis. The company also manages a biosimilar portfolio, including a Herceptin biosimilar licensed to Qilu Pharmaceutical and the Eylea biosimilar Eyluxvi, which received European regulatory approval. Alteogen BioLogics serves as a subsidiary for domestic and international sales and marketing operations.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage alteogen.com
Sector Healthcare IR page alteogen.com
Tags
biosimilars, biobetters, hyaluronidase, subcutaneous injection, antibody-drug conjugates, fusion proteins, ophthalmology, oncology, growth hormone, protein engineering, Hybrozyme, NexP, NexMab, ALT-B4, berahyaluronidase alfa, Tergase, ALT-BB4, Eyluxvi, ALT-L9, ALT-L2, ALT-P1, ALT-M5, Alteogen BioLogics, Keytruda Qlex
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 39.4%
ROI 31.8%
ROIC 21.4%
Profit margin 65.6%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 72.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 215.859B 102.855B 96.523B 28.806B 38.746B 42.426B 29.229B 13.703B 12.104B 6.844B 4.727B 7.043B 5.527B
Net profit 141.666B 60.69B -3.582B -10.078B -11.588B -3.422B -1.738B -7.07B -7.449B -3.587B 1.208B 931.146M 1.606B
Free cash flow 101.121B 50.326B -8.985B -24.298B -23.046B -3.442B 969.616M -16.312B -5.053B -4.099B -1.561B 1.177B 1.437B

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 1.65B 1.45B 4.63B 1.84B 2.69B 4.26B 8.77B 16.7B 20.2B 29.6B
↳ YoY growth +304.1% -12.0% +218.7% -60.3% +46.6% +58.4% +105.6% +90.8% +20.9% +46.6%
↳ 5y CAGR +62.8% +16.7% +45.8% +20.9% +43.3% +29.3% +61.6% +61.6%
Borrowings, current (KRW) 0.00 0.00 300M 3.1B 3.05B 2.55B 3.38B 0.00 1.41B 1.6B
Borrowings, non-current (KRW) 0.00 0.00 1.5B 1B 688M 938M 688M 1.25B 0.00 4.03B
Bonds payable (KRW) — — — — — 0.00 0.00 1.25B 1.41B 1.6B
Lease liabilities (KRW) — — — — — 275M 255M 456M 345M 459M
Cash and deposits (KRW) 8.39B 5.23B 8.92B 4.41B 38.9B 10.5B 45.8B 30.2B 19B 66.4B
Intangible assets (KRW) 2.11B 399M 508M 631M 907M 11.2B 47.2B 89.2B 112B 120B
Right-of-use assets (KRW) — — — — — 289M 285M 488M 372M 521M
Net debt (borrowings + leases - cash) (KRW) -8.39B -5.23B -7.12B -313M -35.2B -6.78B -41.5B -28.5B -17.2B -60.3B
Cash flow detail
Operating cash flow (KRW) -3.16B -4.35B -9.11B 9.13B 1.68B -9.46B -17.9B -7.77B 53B 124B
Purchases of property, plant and equipment (KRW) -940M -707M -7.2B -8.16B -5.12B -13.6B -6.42B -1.22B -2.72B -23B
Purchases of intangible assets (KRW) -1.61B -78.5M -179M -165M -375M -10.5B -36.1B -42.2B -21.7B -10.4B
Share buybacks (cash effect) (KRW) -811M -1.18B 0.00 0.00 — -794M -557M 0.00 0.00 —
Interest paid (cash effect) (KRW) -501,566 -1.86M -24.6M 0.00 -101M -26.4M -102M -266M -123M -141M
Income taxes paid (cash effect) (KRW) -35.1M -103M -81M -191M -25.9M -829M -656M -148M -3.16B -341M
Free cash flow (OCF - PPE - intangibles) (KRW) -5.71B -5.13B -16.5B 804M -3.82B -33.5B -60.4B -51.2B 28.6B 90.7B
Income detail
Total comprehensive income (KRW) -3.59B -7.45B -7.07B -1.74B -3.42B -11.6B -10.1B -3.58B 60.7B 145B
Comprehensive income to owners (KRW) -3.59B -7.45B -6.87B -705M -970M -6.27B -8.15B -3.37B 62.3B 142B
Reported Mar 30, 2017 Mar 30, 2020 Mar 30, 2020 Mar 30, 2020 Aug 10, 2021 Mar 18, 2024 Mar 18, 2024 Mar 18, 2024 Mar 21, 2025 Mar 23, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Alteogen (ticker 196170), listed in South Korea.

ETFs Holding Alteogen

ETF Weight in ETF Shares Market value As of
DFSE 0.06% 2,741 $ 365.48K Nov 12, 2026
DFAE 0.04% 30,619 $ 4.083M Nov 12, 2026
DEHP 0.04% 1,233 $ 164.406K Nov 12, 2026
DFEM 0.03% 17,396 $ 2.32M Nov 12, 2026
AVEM 0.02% 48,373 $ 6.098M Nov 16, 2026
DEXC 0.01% 281 $ 37.468K Nov 12, 2026
AVSE 0.01% 213 $ 26.853K Nov 16, 2026
AVXC 0.01% 403 $ 50.806K Nov 16, 2026
DFAX 0.01% 5,754 $ 767.229K Nov 12, 2026